This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Usv Private Limited. Active years: 2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017
Title: Nitin Nivrutti Hagavane: Innovator in Pharmaceutical Chemistry
Introduction
Nitin Nivrutti Hagavane is a notable inventor based in Mumbai, India. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the synthesis of important compounds. His work has implications for the development of new medications, showcasing his innovative spirit and dedication to advancing healthcare.
Latest Patents
Nitin Nivrutti Hagavane holds a patent for the synthesis of dabigatran. The patent details a process for the preparation of Dabigatran etexilate or its pharmaceutically acceptable salts. The invention also introduces novel compounds, specifically Ethyl-3-{[(2-formyl-1-methyl-1H-benzimidazole-5-yl)carbonyl]-(2-pyridinyl) amino}propanoate and Ethyl-3-{[(2-dichloromethyl-1-methyl-1H-benzimidazole-5-yl)carbonyl]-(2-pyridinyl)amino}propanoate. These compounds are essential for the preparation of Dabigatran etexilate, highlighting the innovative nature of his work. He has 1 patent to his name.
Career Highlights
Nitin Nivrutti Hagavane is currently associated with Usv Private Limited, where he continues to contribute to pharmaceutical research and development. His expertise in synthesis and compound development has positioned him as a valuable asset in his field.
Collaborations
Throughout his career, Nitin has collaborated with notable colleagues, including Nitin Dnyaneshwar Arote and Harish Kashinath Mondkar. These collaborations have further enriched his research and innovation efforts.
Conclusion
Nitin Nivrutti Hagavane exemplifies the spirit of innovation in pharmaceutical chemistry. His contributions, particularly in the synthesis of dabigatran, reflect his commitment to advancing medical science. His work continues to impact the field positively, paving the way for future developments in medication synthesis.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
